Cargando…
2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms
BACKGROUND: The relationship between antimicrobial use and subsequent resistance is complicated; this study assesses the short-term impact of antimicrobial use on fecal carriage of resistant microorganisms. This is a sub-study of an ongoing trial comparing 7 vs. 14 days of antimicrobial treatment fo...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810136/ http://dx.doi.org/10.1093/ofid/ofz360.2261 |
_version_ | 1783462174101864448 |
---|---|
author | Ahmad, Abdul Amundson, Carla Clabots, Connie Porter, Stephen Johnson, James R Drekonja, Dimitri M |
author_facet | Ahmad, Abdul Amundson, Carla Clabots, Connie Porter, Stephen Johnson, James R Drekonja, Dimitri M |
author_sort | Ahmad, Abdul |
collection | PubMed |
description | BACKGROUND: The relationship between antimicrobial use and subsequent resistance is complicated; this study assesses the short-term impact of antimicrobial use on fecal carriage of resistant microorganisms. This is a sub-study of an ongoing trial comparing 7 vs. 14 days of antimicrobial treatment for male urinary tract infection. This analysis quantifies the effect of 1–2 weeks of systemic antimicrobial use on the fecal flora within 1 week of completing therapy. METHODS: The parent study has enrolled 216 subjects, with 178 enrolled in the optional resistance sub-study. Subjects received either ciprofloxacin or trimethoprim/sulfamethoxazole (SXT), randomized to 7 vs. 14 days therapy. Subjects provided 2 stool specimens, 1 during treatment and 1 a week after completing study medication. Samples were plated on media for Gram-positive and negative growth, including T-7 plates with ciprofloxacin and SXT added to select for resistant organisms. Resistance to 22 antimicrobials was assessed, with resistance reported by: number of isolates with any antimicrobial resistance, total number of resistant drugs/isolate, and number of isolates with multi-drug resistance (resistance to 3 or more different antimicrobial classes). RESULTS: Overall, 143 (80%) subjects provided 2 stool samples, with 104 (73%) having growth from at least 1 of the samples. Fifty-one of 143 (36%) had microbial growth from both samples. From these 51 paired samples, there were 255 total strains isolated (117 from the first sample, 138 from the second), with some yielding multiple organisms (range, 1–5). From sample 1, 110/117 (94%) isolates had any antimicrobial resistance, vs. 131/138 (95%) from sample 2 (P = .79). Mean number of resistant drugs/isolate was 7.4 in sample 1 and 5.8 in sample 2 (P = .009). Multi-drug resistance was seen in 102/117 (87%) isolates from sample 1 vs. 85/138 (62%) isolates in sample 2 (P < .001). CONCLUSION: The fecal flora of patients on antimicrobial therapy for UTI has a significant increase in resistant microorganisms compared with samples obtained shortly after antimicrobial completion. This may reflect repopulation of the fecal flora with less-resistant strains after the selection pressure of therapy has been removed. After unblinding, we will assess if differences in resistance are affected by therapy duration. DISCLOSURES: All authors: No reported disclosures. |
format | Online Article Text |
id | pubmed-6810136 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-68101362019-10-28 2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms Ahmad, Abdul Amundson, Carla Clabots, Connie Porter, Stephen Johnson, James R Drekonja, Dimitri M Open Forum Infect Dis Abstracts BACKGROUND: The relationship between antimicrobial use and subsequent resistance is complicated; this study assesses the short-term impact of antimicrobial use on fecal carriage of resistant microorganisms. This is a sub-study of an ongoing trial comparing 7 vs. 14 days of antimicrobial treatment for male urinary tract infection. This analysis quantifies the effect of 1–2 weeks of systemic antimicrobial use on the fecal flora within 1 week of completing therapy. METHODS: The parent study has enrolled 216 subjects, with 178 enrolled in the optional resistance sub-study. Subjects received either ciprofloxacin or trimethoprim/sulfamethoxazole (SXT), randomized to 7 vs. 14 days therapy. Subjects provided 2 stool specimens, 1 during treatment and 1 a week after completing study medication. Samples were plated on media for Gram-positive and negative growth, including T-7 plates with ciprofloxacin and SXT added to select for resistant organisms. Resistance to 22 antimicrobials was assessed, with resistance reported by: number of isolates with any antimicrobial resistance, total number of resistant drugs/isolate, and number of isolates with multi-drug resistance (resistance to 3 or more different antimicrobial classes). RESULTS: Overall, 143 (80%) subjects provided 2 stool samples, with 104 (73%) having growth from at least 1 of the samples. Fifty-one of 143 (36%) had microbial growth from both samples. From these 51 paired samples, there were 255 total strains isolated (117 from the first sample, 138 from the second), with some yielding multiple organisms (range, 1–5). From sample 1, 110/117 (94%) isolates had any antimicrobial resistance, vs. 131/138 (95%) from sample 2 (P = .79). Mean number of resistant drugs/isolate was 7.4 in sample 1 and 5.8 in sample 2 (P = .009). Multi-drug resistance was seen in 102/117 (87%) isolates from sample 1 vs. 85/138 (62%) isolates in sample 2 (P < .001). CONCLUSION: The fecal flora of patients on antimicrobial therapy for UTI has a significant increase in resistant microorganisms compared with samples obtained shortly after antimicrobial completion. This may reflect repopulation of the fecal flora with less-resistant strains after the selection pressure of therapy has been removed. After unblinding, we will assess if differences in resistance are affected by therapy duration. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810136/ http://dx.doi.org/10.1093/ofid/ofz360.2261 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Abstracts Ahmad, Abdul Amundson, Carla Clabots, Connie Porter, Stephen Johnson, James R Drekonja, Dimitri M 2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms |
title | 2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms |
title_full | 2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms |
title_fullStr | 2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms |
title_full_unstemmed | 2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms |
title_short | 2583. Short-term Impact of Antimicrobial Exposure on Fecal Carriage of Resistant Microorganisms |
title_sort | 2583. short-term impact of antimicrobial exposure on fecal carriage of resistant microorganisms |
topic | Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810136/ http://dx.doi.org/10.1093/ofid/ofz360.2261 |
work_keys_str_mv | AT ahmadabdul 2583shorttermimpactofantimicrobialexposureonfecalcarriageofresistantmicroorganisms AT amundsoncarla 2583shorttermimpactofantimicrobialexposureonfecalcarriageofresistantmicroorganisms AT clabotsconnie 2583shorttermimpactofantimicrobialexposureonfecalcarriageofresistantmicroorganisms AT porterstephen 2583shorttermimpactofantimicrobialexposureonfecalcarriageofresistantmicroorganisms AT johnsonjamesr 2583shorttermimpactofantimicrobialexposureonfecalcarriageofresistantmicroorganisms AT drekonjadimitrim 2583shorttermimpactofantimicrobialexposureonfecalcarriageofresistantmicroorganisms |